Abstract 3136: Comprehensive profiling the immune-status of a broad range of in vivo syngeneic models

Abstract

Abstract Latterly with approval of PD-1, PD-L1 antibodies in clinical oncology, immunotherapy has gain recognition for cancer treatment for changing the way by joining chemotherapy, radiation and surgery. This type of cancer treatment aims to produce greater effectiveness with less toxicity than cancer chemotherapy and mainly acts by boosting the body's natural defenses to fight the cancer. It uses substances made by the body or laboratory agent to improve or restore the function of immune system. Therefore, understood the nature immune status and micro environment of in vivo tumor models is very important to assist exploring immunotherapy. As a results, nearly 40 tumor cell lines over a broad range of tumor type as well as corresponding in vivo syngeneic models were intensively studied on its immune status under two conditions when tumor volume were 100 mm3 and 500 to 600mm3 . The effort has been focus on the immune status including T cell status and levels of immune-suppression via FACS analysis of the population of CD4+, CD8+, Treg, MDSC, macrophage and DC cells. Furthermore, not only population of immune cells but also the expressions of immune related gene were analyzed by RE-PCR which are the genes related regulatory of T cells i.e., CD4, Foxp3, GITR; gene of tumor associated macrophage CSF1R, CD68, CX3CR1, ITGAM, CD163, MARC1; gene of co-stimulator receptors of T cells ICOS, CD137(Tnfrsf9), OX40(Tnfrsf4); co-inhibitory receptors of T cell BTLA, HAVCR2, CTLA4, LAG3, CD28, PDCD1; and gene of co-inhibitory ligands of tumor cells CD274, CD137L(Tnfsf9), PDCD1LG2, HVEM(Tnfsf14), OX40L(Tnfsf4). The profiling data illustrated, indeed, the expression of PD-L1 is different on different tumor cells; the immune status certainly pending on the tumor type but also related to the tumor progression. The bigger tumor size the higher level of expression of immune suppression which deterring the immune cell ability to conquer cancer. We believe that this profiling data will help many scientists to properly select correct model to support R&D and to better understand how immune therapeutically agent acts in the immune system. With this comprehensive research data, we're now at a point where this information has started to become translated into treatment possibilities for cancer patients. Citation Format: Jingqi Huang, Shipzong Hu, Wentao Li. Comprehensive profiling the immune-status of a broad range of in vivo syngeneic models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3136.